Relapsed, refractory peripheral T-cell lymphoma not otherwise specified   successfully treated with allogeneic haematopoietic stem cell transplantation

Gooneratne, Lallindra; Gamage, V. N. U.; Silva, M. V. C. De; Karunanayake, P.

doi:10.4038/cmj.v63i2.8672

Cited by 1 publication

(1 citation statement)

References 6 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although stem cell transplantation is a relatively alternative second-line regimen for patients at high risk, the transplantation has a relatively small range of clinical application because most of the disease occur in the patients between the ages of 50 and 60 years with poor physical tolerance. On the other hand, the stem cell transplantation is effective for patients who are sensitive to chemotherapy because achieving complete remission (CR) through induced chemotherapy is necessary before transplantation 7,8. Recently, a number of emerging therapeutic agents and treatment regimens, such as the anti-CD30 antibody, histone deacetylase inhibitors, and immunotherapy, have improved the efficacy of some subtypes of NHL patients and changed the treatment mode of some NHL patients, showing good application prospect, but they are not widely available because of their high price and unacceptable side effects 9,10.…”

Section: Introductionmentioning

confidence: 99%

<p>Gemcitabine, cisplatin, prednisone, and thalidomide for relapse and refractory peripheral T-cell lymphoma: a retrospective study from China</p>

Liu

Shang

et al. 2019

CMAR

View full text Add to dashboard Cite

BackgroundPeripheral T-cell lymphoma (PTCL) is often prone to relapse and progression even after formal first-line treatment, and there is no standard regimen for second-line treatment. What is more, the activity of thalidomide against this type of lymphoma is unknown.PurposeThe objective of this study was to evaluate the efficacy and safety of GDPT regimen in the treatment of relapsed/refractory peripheral T-cell lymphoma.Patients and methodsIn this retrospective study, gemcitabine, cisplatin, prednisone, and thalidomide (GDPT) combination regimen was used as salvage protocol for PTCL that failed in first-line treatment for 29 patients and it was scheduled to give 6 cycles of GDPT therapy in order to better evaluate the efficacy unless there was evidence of disease progression, unacceptable toxicities, or refusal by the patient.ResultsAfter a total of 106 cycles of GDPT regimen were administered, the result showed that the disease control rate (DCR) achieved 82.8% and overall response rate (ORR) reached 69.0% with 34.5% complete remission (CR) and 34.5% partial remission (PR). The median progression-free survival (PFS) was 10.0 months (95% CI 6.6–13.4) and median OS was 28.0 months (95% CI 19.2–36.8). And the 1-year PFS rate and 1-year OS rate were 43.6% and 64.6%, respectively. Both hematologic and non-hematologic toxicities were moderate and well tolerated. There was no treatment-related death.ConclusionThalidomide in combination with gemcitabine, cisplatin, prednisone regimen is a new promising approach to treating patients with relapse and refractory PTCL.

show abstract